Search results
Kristen B. Slaoui, PhD has been the Chief Corporate Development Officer at Galderma, the… | Learn more about Kristen Slaoui's work experience, education, connections & more by visiting their ...
- 500+
- Greater Philadelphia
- 5.1K
- Kristen Belmonte Slaoui Biography
- Kristen Belmonte Slaoui Age and Birthday
- Kristen Belmonte Slaoui Education
- Kristen Slaoui Husband and Son
- Kristen Belmonte Slaoui Net Worth
- Kristen Belmonte Slaoui GSK
- Kristen Belmonte Slaoui Galderma
Kristen Belmonte Slaoui is the Chief Corporate Development Officer at Galderma. Slaoui is also known as Moncef Slaoui’s wife. Moncef Slaoui is an Americanresearcher who previously served as the head of GlaxoSmithKline’s vaccines department.
Belmonte Slaoui was born in July 1970. She is 53 yearsof age as of 2023. Her husband Moncef Slaoui was born on July 22, 1959, making him 64 years as of the time of this writing.
Belmonte Slaoui attended Gettysburg College,a private liberal arts college in Gettysburg, Pennsylvania, where she graduated with a Bachelor’s degree in Biology and Classical Studies. Kristen then furthered her studies at Johns Hopkins Bloomberg School of Public Health in Maryland where she earned a Ph. D in Physiology.
Belmonte Slaoui is married to Moncef Mohamed Slaoui, a Moroccan-born Belgian-American researcher and former head of GlaxoSmithKline’s vaccines department. The couple has a son named Ryan.
According to her LinkedIn, Kristen has executed more than $30 billionworth of deals and acquisitions since joining GSK’s Business Development teams in 2006. We estimate Kristen Belmonte Slaoui’s net worth at $1 million.
Belmonte Slaoui spent 20 years with the British multinational pharmaceutical company GSK. She started out in the research labs, where her work in pulmonary disease resulted in the development of the long-acting muscarinic receptor antagonist in the approved medicines Anoro™ Ellipta™, Incruse™ Ellipta™, and Trelegy™ Ellipta™.
Galderma S.A. is a Swiss pharmaceutical company specializing in dermatological treatments and skincare products, Kristen is the Chief Corporate Development Officer at Galderma a position she secured in September 2020.
Kristen Slaoui is Vice President and Head of Business Development for GlaxoSmithKline’s Global Pharmaceuticals Commercial Portfolio. She has spent nineteen years with GSK, first in R&D, where her work in pulmonary disease resulted in the discovery of the muscarinic receptor antagonist in the approved medicines Anoro™, Incruse™, and Trelegy™.
Kristen Slaoui is Vice President and Head of Business Development for GlaxoSmithKline’s Global Pharmaceuticals Commercial Portfolio. She has spent nineteen years with GSK, first in R&D, where her work in pulmonary disease resulted in the discovery of the muscarinic receptor antagonist in the approved medicines Anoro™, Incruse™, and Trelegy™.
Kristen Slaoui Chief Corporate Development Officer at Galderma 1mo Report this post Join me at Octane's Aesthetic Tech Forum in Newport Beach, CA, set for January 25-26 at the exquisite Balboa Bay ...
Kristen B. Slaoui, PhD has been the Chief Corporate Development Officer at Galderma, the world’s largest independent global dermatology company, since 2020. Since joining Galderma, she oversaw several significant transactions including the acquisition of Alastin Skincare in 2021, adding to Galderma’s premium portfolio. Prior to this role ...
1y. We asked Kristen Slaoui, Head of Corporate Development, Galderma why it is important for Galderma business development to attend IMCAS. To hear more from her, come to the IMCAS Economic World ...
